In glucose-limited microenvironments, digestive system tumors may switch from glycolysis to mitochondrial OXPHOS or FAO, thereby diminishing the efficacy of PKM2 inhibitors and paradoxically enhancing cell survival (43). This evidence concerns the gene PKM and digestive system neoplasm.